Nuvalent (NUVL, $62.76) was a top loser over the last three months, falling -1 to $62.76 per share. A.I.dvisor analyzed 917 stocks in the Biotechnology Industry for the 3-month period ending April 19, 2024, and found that of them () exhibited an Uptrend while of them () demonstrated a Downtrend.